Grail
Menlo Park, California, United States · Biotechnology, Genetics, Health Care
Grail is a healthcare company focused on the early detection of cancer through its innovative liquid biopsy technology. The company aims to transform cancer diagnosis and treatment by providing tools that detect cancer at its earliest stages. Grail's mission is to help save lives through early cancer detection. The firm blends cutting-edge genetic science with next-generation sequencing.
Key facts
- Headquarters
- Menlo Park, California, United States
- Employees
- 1,000
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Public (GRAL)
- Website
- grailbio.com
- Company page
Recent activity at Grail
- : GRAIL, Inc. completes $110 million equity financing led by Samsung entities to support growth and international expansion efforts.
- : GRAIL, Inc. Appoints Josh Ofman as Chief Executive Officer
- : SEC 8-K (1.01): On November 13, 2025, GRAIL, Inc. entered into a securities purchase agreement dated October 18, 2025, which resulted in the issuance of a total of 3,925,767 shares of common stock. This includes 1,927,194 shares of common stock and 1,998,573 shares issuable upon the exercise of pre-funded warrants to purchase shares. These transactions involve several selling stockholders as disclosed in the prospectus supplement. The resale of these securities is being filed with the SEC under Rule 424(b), indicating a significant capital market activity undertaken by the company. The strategic implications suggest potential fundraising or liquidity events for the company in the near future.
- : GRAIL, Inc. has secured $325.0 million in private placement financing to support its cancer detection mission, with lead investor Morgan Stanley. The funding will aid in commercial activities and working capital.
- : SEC 8-K (1.01): On October 18, 2025, GRAIL, Inc. entered into a Securities Purchase Agreement with specified purchasers, referred to as the Investors, for a private placement. Under this agreement, GRAIL agreed to sell a total of 4,639,543 shares of its common stock at a par value of $0.001 per share, and some investors were offered prefunded warrants as an alternative to common shares, with an exercise price set at $0.001 per share. This transaction involves raising capital through securities offerings, marking a strategic move intended to strengthen financial positioning. The agreement could lead to future dilution of existing shares if the prefunded warrants are exercised, impacting shareholders' equity.
- : SEC 8-K (1.01): On October 16, 2025, GRAIL, Inc. entered into a Stock Purchase Agreement with Samsung C&T Corporation, Samsung Electronics Singapore Pte. Ltd., and Samsung Electronics Co., Ltd. The agreement involves the issuance and sale of 1,570,308 shares of common stock at a price of $70.05 per share. This private placement is significant as it represents a substantial capital investment by the Samsung entities in GRAIL, which may enhance GRAIL's operational capabilities and strategic position in the market. The agreement outlines specific terms and conditions that govern the transaction, underscoring its materiality to GRAIL's business operations.
- : Grail's Stock Surges 30% Following Agreement with Quest
- : Grail, Inc.
- : GRAIL Announces $390 Million Series D Financing
- : Grail, Inc.
Grail funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Venture | $110.0M |
| Oct 2025 | Private Equity | $325.0M |
| May 2020 | Venture | $388.4M |
| May 2020 | Series D | $390.0M |
| Dec 2019 | Venture | $125.0M |
Leadership
- Gail Houston, Associate Director - Recruiting (Sourcing, Lead Gen and RC)
- Brad Cillian, Head of US Employer Distribution Partnerships, Director
- Stephanie Guzman, Director
- MIN CUI, Director
- CATHERINE FRIEDMAN, Director
- KAYE FOSTER, Director
- RICHARD KLAUSNER, Director
- WILLIAM RASTETTER, Director
- ROBERT NELSEN, Director
- MAYKIN HO, Director
- HANS BISHOP, Executive Officer, Director
- HAL BARRON, Director
Verified email and direct lines for Grail’s decision-makers are on Fundz. See plans
Employee benefit plans
Grail files 4 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Grail in the news
Companies similar to Grail
- Quantabio · Biotechnology, Genetics, Health Care, Health Diagnostics, research
- Veracyte · Biotechnology, Genetics, Health Care, Health Diagnostics
- 4baseCare · Biotechnology, Genetics, Health Care, Health Diagnostics
- GenePlanet · Biotechnology, Genetics, Health Care, Health Diagnostics
- Devyser · Biotechnology, Genetics, Health Care, Health Diagnostics
About Grail: questions and answers
What does Grail do?
Grail is a healthcare company focused on the early detection of cancer through its innovative liquid biopsy technology. The company aims to transform cancer diagnosis and treatment by providing tools that detect cancer at its earliest stages. Grail's mission is to help save lives through early cancer detection. The firm blends cutting-edge genetic science with next-generation sequencing.
Where is Grail headquartered?
Grail is headquartered in Menlo Park, California, United States.
How many employees does Grail have?
Grail has about 1,000 employees.
Has Grail raised funding?
Yes. Fundz has recorded 5 funding events for Grail. The most recent, $110.0M, was in Jun 2026.
What is the latest news on Grail?
On Jun 25, 2026, GRAIL, Inc. completes $110 million equity financing led by Samsung entities to support growth and international expansion efforts.
Is Grail a public company?
Yes. Grail is publicly traded under the ticker GRAL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy